EUCTR2007-004625-14-NL进行中（未招募）不适用
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy - phase II erlotinib-sorafenib in advanced NSCLC
VU University Medical Centre0 个研究点目标入组 48 人开始时间: 2007年9月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically advanced NSCLC
- •Normal organ function
- •ECOG PS 0-2
- •Age >18 yrs
- •Measurable disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of cardiac disease
- •Symptomatic brain or leptomeningeal metastases
- •History of bleeding diasthesis
研究者
相似试验
尚未招募
2 期
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapyNon small cell lung cancer10038666NL-OMON31390Vrije Universiteit Medisch Centrum48
进行中（未招募）
不适用
A Pilot Study of Erlotinib and Temsirolimus in Patients with Advanced Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based TreatmentSCLCEUCTR2009-017101-11-ATMUW, Klinik für Innere Medizin I, Onkologie20
进行中（未招募）
1 期
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
已完成
不适用
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFRPre-treated non-small cell lung cancer with wild type EGFR and occurred in never or light smokerJPRN-UMIN000005491Hiroshima citizens hospital Department of Medical Oncology40
进行中（未招募）
不适用
A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapyHistologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histological subtypes: adenocarcinoma, planocellular or squamous cell carcinoma, and anaplastic/high-grade or undifferentiated carcinomaEUCTR2006-001308-35-DKThe Finsen Center, Rigshospitalet63